Valuation: Celyad Oncology SA

Capitalization 12.94M 15.03M 11.83M 11.28M 20.69M 1.44B 21.03M 142M 54.91M 685M 56.42M 55.21M 2.39B P/E ratio 2024
-5.06x
P/E ratio 2025 9.44x
Enterprise value 11.23M 13.05M 10.27M 9.79M 17.96M 1.25B 18.25M 123M 47.66M 594M 48.97M 47.92M 2.07B EV / Sales 2024
141x
EV / Sales 2025 281x
Free-Float
30.71%
Yield 2024 *
-
Yield 2025 -
1 day-5.88%
1 week-9.33%
Current month-12.54%
1 month-16.05%
3 months-22.73%
6 months+36.00%
Current year+60.00%
1 week 0.27
Extreme 0.27
0.3
1 month 0.27
Extreme 0.27
0.32
Current year 0.17
Extreme 0.168
0.65
1 year 0.16
Extreme 0.16
0.65
3 years 0.16
Extreme 0.16
1.28
5 years 0.16
Extreme 0.16
5.2
10 years 0.16
Extreme 0.16
56.48
Manager TitleAgeSince
Director of Finance/CFO - 31/12/2018
General Counsel 51 31/08/2021
Director TitleAgeSince
Chairman 69 23/07/2007
Director/Board Member - 31/12/2007
Chairman 61 22/06/2022
Change 5d. change 1-year change 3-years change Capi.($)
-5.88%-9.33%-40.09%-53.90% 15.03M
-0.42%-2.99%-18.60%-19.13% 41.67B
-0.72%-6.64%+24.32%+26.85% 32.6B
-2.22%-1.50%+255.60%+459.46% 30.97B
+3.32%+0.32%+21.29%-10.92% 28.23B
-2.97%-7.66%+23.72%+16.45% 26.41B
-1.97%-0.53% - - 14.94B
-1.03%+5.18%+210.30%+4,548.29% 14.13B
-2.29%-3.85%+112.97%+97.86% 12.27B
+1.38%+2.70%+7.55%-0.13% 12.12B
Average -1.29%-2.47%+66.34%+562.76% 21.34B
Weighted average by Cap. -0.72%-2.66%+68.59%+402.74%

Financials

2024 2025
Net sales 186K 216K 170K 162K 297K 20.74M 302K 2.04M 790K 9.84M 811K 794K 34.3M 21K 24.4K 19.2K 18.32K 33.58K 2.34M 34.14K 230K 89.14K 1.11M 91.58K 89.62K 3.87M
Net income -5.82M -6.77M -5.32M -5.08M -9.31M -649M -9.47M -63.89M -24.72M -308M -25.4M -24.86M -1.07B 830K 965K 759K 724K 1.33M 92.54M 1.35M 9.1M 3.52M 43.93M 3.62M 3.54M 153M
Net Debt -3.3M -3.83M -3.01M -2.87M -5.27M -367M -5.36M -36.14M -13.99M -174M -14.37M -14.06M -608M -1.71M -1.98M -1.56M -1.49M -2.73M -190M -2.78M -18.74M -7.25M -90.4M -7.45M -7.29M -315M
Logo Celyad Oncology SA
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Employees
5
Date Price Change Volume
18/05/26 0.2720 -5.88% 17,935
15/05/26 0.2890 0.00% 12,294
14/05/26 0.2890 -0.69% 9,679
13/05/26 0.2910 -1.69% 23,627
12/05/26 0.2960 -1.33% 8,619